Crowdfunding helps seven-month-old SMA patient access ₹10 crore gene therapy

What happened to the seven-month-old infant, and what treatment did the child receive?

A seven-month-old infant diagnosed with Spinal Muscular Atrophy at five weeks received a one-time gene replacement treatment. The therapy was given at Aster CMI Hospital in Bengaluru. This mattered because SMA can progressively damage motor neurons and weaken movement, swallowing, and breathing muscles. Early treatment aims to preserve motor-neuron function before more damage occurs.

The child weighed 6.8 kg during treatment and received onasemnogene abeparvovec. The therapy delivers a functional copy of the SMN1 gene, allowing cells to produce the SMN protein needed for motor-neuron survival. Before gene therapy, the infant received risdiplam and supportive care while the team completed evaluation and preparation.

The treatment cost around ₹10 crore, which was beyond the family’s means. Public contributions raised the entire amount through crowdfunding. The case highlights the importance of early diagnosis, prompt treatment, careful evaluation, and multidisciplinary monitoring for children with SMA.

What is spinal muscular atrophy, and how does it affect a child’s muscles and movement?

Spinal Muscular Atrophy is a rare inherited neuromuscular disorder. It progressively affects motor neurons, which are nerve cells responsible for controlling muscle movement. SMA is most commonly linked to abnormalities in the SMN1 gene, causing inadequate production of the SMN protein. This makes the condition especially serious during infancy, when children are developing basic movement skills.

Affected infants can develop muscle weakness and have difficulty reaching milestones. These may include holding the head up, sitting, and moving independently. In severe cases, weakness can also affect muscles used for swallowing and breathing. The article’s infant was diagnosed at five weeks after clinical assessment and genetic testing.

SMA can worsen over time, so early diagnosis matters. The treating team began disease-modifying treatment promptly, first using risdiplam and later gene replacement therapy. The case shows how recognizing symptoms early and confirming the diagnosis genetically can support faster treatment and potentially better motor outcomes.

How much did the gene replacement therapy cost, and how was the money raised?

The gene replacement therapy cost around ₹10 crore, according to the hospital. This extraordinary expense created a major barrier for the family after the infant’s SMA diagnosis. The case shows that medical progress does not automatically mean treatment is financially accessible, especially when a therapy requires a large one-time payment.

Because the family could not afford the treatment, they turned to crowdfunding. People who had no personal connection with the family contributed to the campaign. Their donations collectively raised the full amount needed for the child’s treatment at Aster CMI Hospital in Bengaluru.

The funding outcome allowed the infant to receive onasemnogene abeparvovec at seven months. It also highlights the financial challenges surrounding newer gene therapies. Early diagnosis and medical preparation were important, but community support was essential in making the planned treatment possible for this family.

How does onasemnogene abeparvovec use a functional copy of the SMN1 gene to treat SMA?

Onasemnogene abeparvovec is a gene replacement therapy used to address the genetic cause of SMA. SMA is most commonly caused by abnormalities in the SMN1 gene, which lead to inadequate production of the SMN protein. Without enough of this protein, motor neurons are not adequately supported and muscle movement can progressively weaken.

The therapy delivers a functional copy of SMN1 into cells. This copy enables cells to produce the SMN protein required for motor-neuron survival. By targeting the underlying genetic problem, the treatment differs from care focused only on managing symptoms or supporting affected functions.

The infant’s treatment involved pre-treatment evaluation, weight-based dosing, and close multidisciplinary monitoring during and after administration. The child had first received risdiplam and supportive care while being assessed for gene replacement. Early administration was considered important because earlier treatment is generally associated with better motor outcomes.

Why can diagnosing SMA and beginning treatment in the first weeks of life improve a child’s motor outcomes?

Early diagnosis can matter because SMA progressively affects motor neurons, the nerve cells that control muscle movement. If motor-neuron function declines, infants may develop weakness and struggle with head control, sitting, or independent movement. Severe disease can also affect swallowing and breathing. Beginning treatment quickly aims to preserve function before greater weakness develops.

In this case, clinical assessment and genetic testing confirmed SMA when the infant was five weeks old. The treating team started risdiplam and supportive care while evaluating the child for gene replacement therapy. The infant later received onasemnogene abeparvovec at seven months, after preparation and assessment.

The hospital’s paediatric neurologist said earlier treatment is generally associated with better motor outcomes. The case therefore illustrates why prompt suspicion, genetic confirmation, and rapid treatment planning matter. Early care cannot erase the diagnosis, but it can help protect motor-neuron function during an important developmental period.

What roles do the SMN1 gene and the SMN protein normally play in keeping motor neurons alive?

The article identifies SMN1 as the gene most commonly involved in SMA. When this gene has abnormalities, cells produce too little Survival Motor Neuron, or SMN, protein. The article describes SMN protein as required for motor-neuron survival. Motor neurons are the nerve cells that control muscle movement, so their health is central to a child’s strength and development.

In normal function, SMN1 provides the genetic instructions that enable cells to make SMN protein. Adequate SMN protein supports the survival of motor neurons. In SMA, inadequate production weakens this support. The resulting motor-neuron problems can lead to muscle weakness and difficulty holding the head up, sitting, or moving independently.

Onasemnogene abeparvovec is designed to address this mechanism. It delivers a functional copy of SMN1, enabling cells to produce the needed protein. The article does not detail every cellular role of SMN protein, but it clearly links the gene, the protein, and motor-neuron survival.

Why are advanced gene therapies so expensive, and how can crowdfunding help families access treatments that ordinary insurance or household income may not cover?

Advanced gene therapies can be difficult for families to afford because they are specialised treatments designed to address an underlying genetic cause. The article describes pre-treatment evaluation, weight-based dosing, and close multidisciplinary monitoring for onasemnogene abeparvovec. It also reports a one-time treatment cost of around ₹10 crore, creating a severe financial challenge for the family.

In this case, ordinary household resources were insufficient. The family turned to crowdfunding after the infant’s SMA diagnosis. People with no personal connection contributed to the campaign, and their combined donations raised the entire amount needed for treatment. This made gene replacement possible at Aster CMI Hospital in Bengaluru.

Crowdfunding can therefore act as a bridge when a treatment’s cost exceeds a family’s means or available coverage. However, the case also shows a wider access problem. Early diagnosis and effective therapies matter only when families can obtain them, making affordability and financial support important parts of SMA care.

Key Facts:

📌 The infant was diagnosed with SMA at five weeks of age.

📌 Onasemnogene abeparvovec was administered at seven months.

📌 Crowdfunding raised the entire treatment cost.

📌 SMA progressively affects motor neurons controlling muscle movement.

📌 Infants may struggle to hold their heads up or sit.

📌 Severe SMA can affect swallowing and breathing muscles.

📌 The hospital reported an overall treatment cost of around ₹10 crore.